chr7-92040795-C-T
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_005751.5(AKAP9):c.4814C>T(p.Thr1605Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000174 in 1,613,528 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_005751.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AKAP9 | NM_005751.5 | c.4814C>T | p.Thr1605Met | missense_variant | 18/50 | ENST00000356239.8 | NP_005742.4 | |
AKAP9 | NM_147185.3 | c.4814C>T | p.Thr1605Met | missense_variant | 18/50 | NP_671714.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AKAP9 | ENST00000356239.8 | c.4814C>T | p.Thr1605Met | missense_variant | 18/50 | 1 | NM_005751.5 | ENSP00000348573 | P4 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151684Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000557 AC: 14AN: 251206Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135748
GnomAD4 exome AF: 0.0000178 AC: 26AN: 1461844Hom.: 0 Cov.: 34 AF XY: 0.0000193 AC XY: 14AN XY: 727222
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151684Hom.: 0 Cov.: 31 AF XY: 0.0000270 AC XY: 2AN XY: 74030
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, no assertion criteria provided | provider interpretation | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Aug 01, 2017 | Testing was performed at the Invitae laboratory. Given the weak gene-disease association, type of variant, and frequency in gnomAD, we consider this variant a variant of uncertain significance, likely benign and we do not feel it is suitable for assessing risk in healthy relatives ("predictive genetic testing"). Gene-level evidence (CC Nov 2015): AKAP9 is a proposed long QT gene. Per Invitae, it has limited evidence as a long QT gene. Of note, there is only one AKAP9 variant in ClinVar classified as likely pathogenic or pathogenic by a clinical laboratory (Blueprint). ExAC constraint analyses of AKAP9 appears to be tolerant to missense variation (Z= -2.75), as well as loss of function/truncating variation (pLI=0.00). The variant has not been seen in any cases of ARVC or other inherited cardiovascular disease (per PubMed and Google). In silico analysis do not agree on the effect on protein function. The Thr is moderately conserved. The variant is reported in 14 of 138,374 individuals listed in the Genome Aggregation Consortium Dataset (gnomAD; http://gnomad.broadinstitute.org/), which currently includes variant calls on >140,000 unrelated individuals of African, Asian, European, Latino, and Ashkenazi descent. Specifically the variant has been seen in 14 of 9433 East Asian individuals (MAF = 0.07421%). There is good coverage at that site. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 26, 2023 | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant does not alter protein structure/function - |
Long QT syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 16, 2022 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The methionine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 190483). This variant has not been reported in the literature in individuals affected with AKAP9-related conditions. This variant is present in population databases (rs777627168, gnomAD 0.07%), and has an allele count higher than expected for a pathogenic variant. This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 1605 of the AKAP9 protein (p.Thr1605Met). - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 16, 2021 | The p.T1605M variant (also known as c.4814C>T), located in coding exon 18 of the AKAP9 gene, results from a C to T substitution at nucleotide position 4814. The threonine at codon 1605 is replaced by methionine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species; however, methionine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at